Overall Status

Active, not recruiting (2)

Terminated (1)

Phase

phase 2 (2)

phase 1 (1)

Sponsor

National Cancer Institute (NCI) (2)

University of Chicago (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

laboratory biomarker analysis (2)

lmb-100 (1)

mesothelin expression (1)

pembrolizumab (1)

pharmacogenomic study (1)

tivantinib (1)

tofacitinib (1)

Study Documents

Intervention Type

drug (2)

other (2)

biological (1)

device (1)

Funder Type

NIH (2)

Other (1)

Study Type

Interventional (3)

epithelioid mesothelioma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma Trial in Chicago (Pembrolizumab, Laboratory

Active, not recruiting

Biphasic Mesothelioma
+9 more

Pembrolizumab
+2 more

Chicago, Illinois

University of Chicago

Apr 18, 2022

Tumors With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic Trial run by the NCI (LMB-100,

Active, not recruiting

Has Results

Neoplasms With Mesothelin Expression
+3 more

LMB-100
+2 more

Bethesda, Maryland

National Institutes of Health Clinical Center

Jan 18, 2022

Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma Trial in United States (Laboratory

Terminated

Has Results

Epithelioid Mesothelioma
+5 more

Laboratory Biomarker Analysis
Tivantinib

Duarte, California
+17 more

Aug 26, 2016